Key Highlights
- 10.54% is the move in Larimar Therapeutics, Inc. (NASDAQ:LRMR) in today's session on November 18, 2026, lifting the traded price to USD 3.31 from a calculated prior close of USD 2.99, a calculated USD 0.32 gain.
- 833.42K shares changed hands in Larimar Therapeutics, Inc. (NASDAQ:LRMR) today, after a gap of 1.34% below the prior close at the open and a further 12.03% move since the open, a calculated opening price near USD 2.95.
- 104.6 million shares outstanding at the latest quarterly filing imply a calculated market Capitalization near USD 346.2 million at the traded price of USD 3.31 for Larimar Therapeutics, Inc. (NASDAQ:LRMR), a clinical-stage company.
- 128.7 million dollars is the cash, equivalents and marketable securities balance at September 30, 2026, set against a third quarter net loss of USD 31.1 million and runway guided into late the second quarter of 2027.
What Moved Larimar Therapeutics, Inc. (NASDAQ:LRMR) in Trading on November 18, 2026 (+USD 0.32, +10.54%)
The traded price of Larimar Therapeutics, Inc. (NASDAQ:LRMR) in today's session on November 18, 2026 is USD 3.31, a move of +10.54% on Volume of 833.42K shares. On a calculated basis, the prior close was USD 2.99 (USD 3.31 divided by 1.1054) and the USD move is +USD 0.32 (price minus prior close). The shares opened 1.34% below the prior close, a calculated USD 2.95, and traded 12.03% above the open. Calculated market capitalization is about USD 346.2 million (104.6 million shares times USD 3.31).
The Rationale: No Same-Day Catalyst After the Nomlabofusp BLA Completion for Larimar Therapeutics, Inc. (NASDAQ:LRMR)
No catalyst specific to the November 18, 2026 session was identified in published coverage. Recent company news centers on nomlabofusp, its candidate for Friedreich ataxia. The rolling Biologics License Application was completed in November 2026 seeking accelerated approval, with FDA filing acceptance anticipated in early 2027 and a potential U.S. launch targeted for the third quarter of 2027 if approved. The company also published its third quarter update on November 16, 2026. As general context, clinical-stage biotechnology shares often move sharply around regulatory milestones and financing expectations.
Valuation, Liquidity and Risks for Larimar Therapeutics, Inc. (NASDAQ:LRMR)
The latest reported period is the third quarter ended September 30, 2026. The net loss was USD 31.1 million, the nine-month net loss was USD 93.5 million, Research and Development expense was USD 25.9 million and general and administrative expense was USD 6.5 million. Cash of USD 128.7 million is forecast to fund operations into late the second quarter of 2027, and the filing contains substantial doubt language about continuing as a going concern. USD 96.9 million of at-the-market capacity remains, so dilution risk persists.
Where Things Stand
Larimar Therapeutics, Inc. (NASDAQ:LRMR) traded at USD 3.31 today, November 18, 2026, up 10.54% from a calculated prior close of USD 2.99, on volume of 833.42K shares. No catalyst specific to the session was identified in published coverage. The latest reported quarter, ended September 30, 2026, showed a net loss of USD 31.1 million and cash of USD 128.7 million, while the nomlabofusp BLA submission was completed in November 2026. Going-concern language, an at-the-market program with USD 96.9 million of capacity and regulatory timing are the key variables. As a pre-revenue biotechnology company it carries high volatility, and this article is not Investment advice.






Please wait processing your request...